Aurobindo receives tough news about FDA inspection

FDA Building 2
The FDA has tagged its inspection of the Aurobindo solids Unit 7 solids formulation plant in India as Official Action Indicated. (FDA)

An FDA inspection of an Aurobindo Pharma manufacturing facility last fall noted more than half a dozen concerns, but at the time the drugmaker indicated they should all be quickly fixable. Now that seems less certain.

The drugmaker today reported that it has received a letter that the agency has classified the inspection of the plant “Official Action Indicated,” a label that means inspectors will recommend the agency take regulatory action.

RELATED: Don't wait up. FTC delays Novartis' Sandoz deal with Aurobindo into 2020: report

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

The drugmaker says it still believes FDA action will not have any significant impact on its revenues or the supplies for its U.S. business, at least “at this juncture.” It again pledged to work closely with the FDA to resolve the seven observations at its Unit 7 solids formulation plant. 

The action comes as Aurobindo is waiting to complete its $1 billion deal for many of the U.S. generic drugs sold by Novartis’ Sandoz in the U.S. as well as three manufacturing sites. That deal was announced in 2018 but has been repeatedly delayed by Federal Trade Commission issues.

RELATED: Aurobindo gets warning letter over valsartan recall mess

Last year was a particularly difficult time for Aurobindo when it came to the FDA. Inspections of Aurobindo’s facilities in India resulted in at least half a dozen Form 483’s and a warning letter, according to FDA records. 

The warning letter was issued for Aurobindo’s facility in the Srikakulam district for issues the FDA said contributed to its valsartan products being tainted with a suspected carcinogen.  

Suggested Articles

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.

The antidepressant Zoloft and its generics are in short supply as the COVID-19 pandemic has caused higher demand and manufacturing interruptions.

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.